PARP1 and ovarian cancer: In fact, pharmacological inhibition of PARP by olaparib in HEY and A2780 ovarian cancer cells (which carry wild-type BRCA1/2 [76]) significantly downregulated the expression of SLC7A11 and GPX4 and increased p53 expression, which promoted ferroptosis and DNA damage and led to cell apoptosis.